NHS National Generic Pharmaceuticals Wave 13

Descriptions

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13Offer reference number: CM/PHG/17/5532Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.Potential periods of call-offs under the framework agreement:Transition (Everolimus)CESW: 1 March 2022 – 30 September 2023 (19 months)LSNE: 1 March 2022 – 31 January 2023 (11 months)NWLN: 1 March 2022 – 31 January 2023 (11 months)Oral Products plus non-parenteralsAll Regions: 1 March 2022 - 31 May 2024 (27 months)Hospital Only ProductsCESW: 1 February 2022 – 30 September 2023 (20 months)LSNE: 1 February 2022 – 31 May 2024 (28 months)NWLN: 1 February 2022 – 31 January 2023 (12 months)